Drug-drug interactions with glucagon-like peptide-1 receptor agonists;Interacciones con medicamentos de los agonistas del receptor del péptido-1 similar a glucagón

Annals of Pharmacotherapy

Volumn 46, Issue 5, 2012, Pages 710-717

  Hurren, Kathryn M ^a   Pinelli, Nicole R ^a  

^a WAYNE STATE UNIVERSITY   (United States)

Author keywords

Albiglutide; Exenatide; Gastric emptying; Glucagon like peptide 1; Incretins; Interaction; Liraglutide; Lixisenatide; Type 2 diabetes

Indexed keywords

ALBIGLUTIDE; ATORVASTATIN; DIGOXIN; ETHINYLESTRADIOL PLUS LEVONORGESTREL; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GRISEOFULVIN; LIRAGLUTIDE; LISINOPRIL; LIXISENATIDE; MEVINOLIN; PARACETAMOL; WARFARIN;

AREA UNDER THE CURVE; BIOEQUIVALENCE; DIABETIC PATIENT; DRUG BLOOD LEVEL; DRUG EXPOSURE; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; PHARMACODYNAMICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SINGLE DRUG DOSE; STEADY STATE;

DIABETES MELLITUS, TYPE 2; DRUG INTERACTIONS; HUMANS; HYPOGLYCEMIC AGENTS; PRESCRIPTION DRUGS; RECEPTORS, GLUCAGON;

EID: 84860996722     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1Q583     Document Type: Review

References (23)

1. Danaei G, Finucane MM, Lu Y, et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet 2011;378:31-40.
2. Nauck MA, Wollschlager D, Werner J, et al. Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM. Diabetologia 1996;39:1546-1553.
3. Product information. Byetta (exenatide). San Diego, CA: Amylin Pharmaceuticals, Inc., October 2009.
4. Product information. Victoza (liraglutide). Princeton, NJ: Novo Nordisk, Inc., January 2010.
5. Madsbad S, Kielgast U, Asmar M, Deacon CF, Torekov SS, Holst JJ. An overview of once-weekly glucagon-like peptide-1 receptor agonists- available efficacy and safety data and perspectives for the future. Diabetes Obes Metab 2011;13:394-407.
6. Ratner RE, Rosenstock J, Boka G. Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial. Diabet Med 2010;27:1024-1032.
7. Linnebjerg H, Park S, Kothare PA, et al. Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes. Regul Pept 2008;151:123-129.
8. Flint A, Kapitza C, Hindsberger C, Zdravkovic M. The once-daily human glucagon-like peptide-1 (GLP-1) analog liraglutide improves postprandial glucose levels in type 2 diabetes patients. Adv Ther 2011;28:213-226.
9. Drucker DJ, Buse JB, Taylor K, et al. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet 2008;372:1240-1250.
10. Neumiller JJ. Clinical pharmacology of incretin therapies for type 2 diabetes mellitus: implications for treatment. Clin Ther 2011;33:528-576.
11. Blase E, Taylor K, Gao H Y, Wintle M, Fineman M. Pharmacokinetics of an oral drug (acetaminophen) administered at various times in relation to subcutaneous injection of exenatide (exendin- 4) in healthy subjects. J Clin Pharmacol 2005;45:570-577.
12. Kothare PA, Soon DK, Linnebjerg H, et al. Effect of exenatide on the steady-state pharmacokinetics of digoxin. J Clin Pharmacol 2005;45:1032-1037.
13. Kothare PA, Linnebjerg H, Skrivanek Z, et al. Exenatide effects on statin pharmacokinetics and lipid response. Int J Clin Pharmacol Ther 2007;45: 114-1120.
14. Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin- 4) on glycemic control over 30 weeks in sulfony-lurea-treated patients with type 2 diabetes. Diabetes Care 2004;27:2628-2635.
15. Kothare P, Seger M, Mace K, et al. Effects of exenatide on the pharma-cokinetics of a combination oral contraceptive in healthy women (abstract 554). AAPS Pharm Sci 2007;9(S2).
16. Linnebjerg H, Kothare P, Park S, Mace K, Mitchell M. The effect of ex-enatide on lisinopril pharmacodynamics and pharmacokinetics in patients with hypertension. Int J Clin Pharmacol Ther 2009;47:651-658.
17. DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin- 4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005;28:1092-1100.
18. Kendall DM, Riddle MC, Rosenstock J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005;28:1083-1091.
19. Soon D, Kothare PA, Linnebjerg H, et al. Effect of exenatide on the phar-macokinetics and pharmacodynamics of warfarin in healthy Asian men. J Clin Pharmacol 2006;46:1179-1187.
20. Jacobsen LV, Vouis J, Hindsberger C, Zdravkovic M. Treatment with li-raglutide, a once-daily GLP-1 analog, does not reduce the bioavailability of ethinyl estradiol/levonorgestrel taken as an oral combination contraceptive drug. J Clin Pharmacol 2011;51:1696-1703. Epub 12 Jan 2011. DOI 10.1177/0091270010389471
21. Malm-Erjefalt M, Ekblom M, Brondsted L, Vouois J, Lennernas H, Zdravkovic M. A randomized, double-blind, cross-over trial investigating the effect of liraglutide on the absorption pharmacokinetics of concomitant-ly administered oral drugs in healthy subjects (abstract). Diabetes 2008; 57(suppl 1):A130.
22. Liu Y, Ruus P, Steinstraesser A, Teichert L. Effect of the GLP-1 agonist lixisenatide on the pharmacokinetics of warfarin (abstract). Diabetes 2010;59(suppl 1):2128.
23. Bush M, Scott R, Zhi H, Watanalumlerd P, Lewis E. Drug-drug interactions of albiglutide, a long-acting GLP-1 receptor agonist with warfarin and digoxin in healthy subjects (abstract). Diabetes;60(suppl 1):2261.